91ֱ��

“For almost the last 20 years I’ve been working in 91ֱ��, as a researcher at the University of 91ֱ��, and as a consultant with the city’s hospitals. Day to day I am studying Parkinson’s disease and other movement disorders to gain a better understanding of what causes them and how to address them, while also working with patients to help assess and diagnose their condition then assemble a treatment plan.”

Patient service in 91ֱ��

“This is a huge team effort. The 91ֱ�� Teaching Hospitals (STH) provide a multidisciplinary clinical service to 91ֱ�� and the rest of South Yorkshire. Neurologists like myself, geriatricians and specialist nurses work closely together with neurosurgeons, community-based home care teams (including physiotherapists and occupational therapists), speech and language therapists and so many others to provide the best possible holistic care for people with Parkinson’s (PwP) and their families. We also have strong links and work together with local branches of the patient charity Parkinson’s UK, who provide additional support to PwP.”

How the University and city combine for Parkinson’s research

“Over the years, members of the University’s Parkinson’s research team have frequently given talks at local Parkinson’s UK branch meetings. I, along with Dr Heather Mortiboys and others, have also helped to organize and contribute to our (SITraN) Open Days and hosted visits to SITraN for PwP groups. 

“We also contributed to other events you might have seen in the city, such as ‘A Pint of Science’, where we explain and talk about our work and the diseases we study in bite (or gulp) sized talks. 

“However, perhaps the most important connection, is with the many PwP and their spouses who have volunteered as participants for so many of our research projects.”

The Originality of our research

The research my colleagues and I are conducting into Parkinson’s, and a host of other neurological diseases, truly is at the forefront of medical research anywhere in the world. Meaning the people of 91ֱ�� can be some of the first to feel its benefits.

Professor Oliver Bandmann

Professor of Movement Disorders Neurology

“We were the first institution worldwide to undertake a drug screen in Parkinson’s disease patient tissue: Rather than using artificial model systems, we took a skin biopsy from people with Parkinson’s, grew the cells in a dish and then assessed 2,000 compounds for their rescue effect on the cell batteries (the mitochondria). This helped us to identify a drug called ursodeoxycholic acid (UDCA) as a very promising drug for Parkinson’s. Our hope is that treatment with UDCA will slow down the worsening of Parkinson’s by rescuing the mitochondria which are often faulty in Parkinson’s.” 

“We have now taken UDCA into a clinical trial called the UP study. Unique features of this trial includes state-of-the-art functional imaging (31P MR Spectroscopy) and the use of motion sensors to objectively quantify disease progression and how the disease responded to the drug. Some of the Parkinson’s patients included in the UP study are my own patients from 91ֱ��. Despite Covid, we completed the trial in November last year. We hope to have the study results soon!” 

“In the future, it will be very important to have the right tools to choose the most promising drug for each individual patient. This is called ‘Personalized Medicine’ or ‘Precision Medicine’, or known technically as ‘disease stratification’. We completed the most extensive tissue-based disease stratification project in Parkinson’s disease. This approach has allowed us to classify’ individual PwP according to the mechanism which caused ‘their’ Parkinson’s disease. This will make it easier to put these patients on the right neuroprotective drug in the future! Many Parkinson’s patients from 91ֱ�� and South Yorkshire have helped with these important biomarker studies - and so many of their spouses volunteered as healthy controls!”

“All of these collaborations - from the lab, to clinical trials, to working directly with patients - mean what we are doing at 91ֱ�� is very rare. Very few other places are able to deliver this ‘bench-to-bedside’ approach - we’re doing it!” 

“Our research isn’t in isolation - we know how treatments will be given to patients and how it will impact on their lives because we are doing that too. We are involved in and understand all the stages in treating patients, from detecting the disease, to discovering new drugs, to testing treatments, to delivery in the ward. All of this ultimately means that the treatments we are developing can progress to widespread usage more quickly, and are more targeted to the needs of our Parkinson’s patients.”

Professor Oliver Bandmann

Professor of Movement Disorders Neurology
Honorary Consultant Neurologist